Nav: Home

A protein could be key to preserving heart function in Duchenne muscular dystrophy

August 01, 2018

SAN ANTONIO, TEXAS, Aug. 1, 2018 -- A protein known to drive nerve cell survival in the brain and spinal cord might also protect failing hearts in children and young adults with Duchenne muscular dystrophy, according to preliminary research presented at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions, a premier global exchange of the latest advances in basic cardiovascular science.

Children with Duchenne muscular dystrophy often begin to lose muscle strength and function between ages three and five. Duchenne cardiomyopathy follows, in which patients' heart muscles stiffen and lose function. Cardiomyopathy often leads to heart failure and death in children and young adults with the disease.

It's hard to predict when cardiomyopathy will happen in Duchenne patients, but when it does, there are no effective or specific treatments aimed at preserving heart function at this time, according to study author Cristi L. Galindo, Ph.D., M.B.A., research assistant professor of medicine at Vanderbilt University Medical Center in Tennessee. Gaining a greater understanding of how cardiomyopathy occurs in these patients could help to develop future treatment.

Galindo and colleagues studied a small group of Duchenne muscular dystrophy patients and measured blood levels of the protein brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin kinase B (TrKB). The receptor, TrKB, attaches to BDNF which then sends chemical signals to the cells to protect against cell death. They noted that BDNF seemed to increase initially in patients whose hearts were still functioning but decreased as patients' heart function declined.

"Researchers have long known that BDNF is important for brain function. It helps brain cell survival and growth and promotes memory. Our research shows BDNF also appears to be heart protective and heart specific. Data suggests the more there is, the better the heart function in the patient," Galindo said.

In addition, researchers examined whether it was possible to increase BDNF and if it might preserve heart function in these patients by studying mice that mimicked human Duchenne patients' disease progression.

The researchers gave mice a plant-derived compound, the TrkB agonist 7,8-dihydroxyflavone (DHF), that binds to the TrkB receptor, mimicking the cell-preserving activity that occurs when BDNF binds to the receptor. The compound was administered orally for 26 weeks in the mice's drinking water.

"The fact that DHF can be delivered orally is important for Duchenne patients," she said. "These children are suffering from muscle degeneration. You don't want to poke them every five minutes."

Echocardiography showed DHF preserved the heart's function, compared to mice that didn't receive DHF. When researchers gave mice the TrkB inhibitor K252a, the opposite occurred and heart function declined.

In general, Galindo and colleagues found BDNF and TrkB are required for the heart's strong and vigorous contraction (contractility) and survival of cardiomyocytes - the heart's cells.
-end-
If the research about using DHF as treatment pans out in humans, BDNF therapy that supplements or activates BDNF signaling could be a new way to treat Duchenne cardiomyopathy. The next steps, according to Galindo, are to test more potent compounds in larger animals.

Co-authors are Cassandra P. Awgulewitsch, B.S.; Jonathan H. Soslow, M.D.; Lin Zhong, M.D., Ph.D.; Erica J. Carrier, Ph.D.; Anand P. Singh, Ph.D.; Prachi Umbarkar, Ph.D.; Qinkun Zhang, M.D.; Frank Raucci, M.D., Ph.D.; Larry W. Markham, M.D.; Hind Lal, Ph.D.; and Antonis K. Hatzopoulos, Ph.D.

This study did not receive outside funding. Author disclosures are on the abstract.

Additional Resources:

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke - the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.

American Heart Association

Related Heart Failure Articles:

New hope for treating heart failure
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Smoking may lead to heart failure by thickening the heart wall
Smokers without obvious signs of heart disease were more likely than nonsmokers and former smokers to have thickened heart walls and reduced heart pumping ability.
After the heart attack: Injectable gels could prevent future heart failure (video)
During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells in the heart.
Heart failure after first heart attack may increase cancer risk
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study today in the Journal of the American College of Cardiology.
Scientists use 'virtual heart' to model heart failure
A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death.
Increase in biomarker linked with increased risk of heart disease, heart failure, death
In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of six-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.

Related Heart Failure Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...